HEADER HYDROLASE/TRANSFERASE 13-JAN-00 1DTQ TITLE CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH PETT- TITLE 2 1 (PETT131A94) COMPND MOL_ID: 1; COMPND 2 MOLECULE: HIV-1 RT A-CHAIN; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: P66; COMPND 5 ENGINEERED: YES; COMPND 6 MOL_ID: 2; COMPND 7 MOLECULE: HIV-1 RT B-CHAIN; COMPND 8 CHAIN: B; COMPND 9 FRAGMENT: P51; COMPND 10 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 EXPRESSION_SYSTEM: BACTERIA; SOURCE 5 EXPRESSION_SYSTEM_COMMON: EUBACTERIA; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 2; SOURCE 7 MOL_ID: 2; SOURCE 8 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 9 ORGANISM_TAXID: 11676; SOURCE 10 EXPRESSION_SYSTEM: BACTERIA; SOURCE 11 EXPRESSION_SYSTEM_COMMON: EUBACTERIA; SOURCE 12 EXPRESSION_SYSTEM_TAXID: 2 KEYWDS HIV-1 REVERSE TRANSCRIPTASE AIDS, NON-NUCLEOSIDE INHIBITOR, DRUG KEYWDS 2 DESIGN, HYDROLASE-TRANSFERASE COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR J.REN,J.DIPROSE,J.WARREN,R.M.ESNOUF,L.E.BIRD,S.IKEMIZU,M.SLATER, AUTHOR 2 J.MILTON,J.BALZARINI,D.I.STUART,D.K.STAMMERS REVDAT 4 20-NOV-24 1DTQ 1 REMARK LINK REVDAT 3 12-NOV-14 1DTQ 1 HET HETATM HETNAM HETSYN REVDAT 3 2 1 MODRES FORMUL REMARK VERSN REVDAT 3 3 1 LINK SEQRES JRNL REVDAT 2 24-FEB-09 1DTQ 1 VERSN REVDAT 1 20-MAR-00 1DTQ 0 JRNL AUTH J.REN,J.DIPROSE,J.WARREN,R.M.ESNOUF,L.E.BIRD,S.IKEMIZU, JRNL AUTH 2 M.SLATER,J.MILTON,J.BALZARINI,D.I.STUART,D.K.STAMMERS JRNL TITL PHENYLETHYLTHIAZOLYLTHIOUREA (PETT) NON-NUCLEOSIDE JRNL TITL 2 INHIBITORS OF HIV-1 AND HIV-2 REVERSE TRANSCRIPTASES. JRNL TITL 3 STRUCTURAL AND BIOCHEMICAL ANALYSES. JRNL REF J.BIOL.CHEM. V. 275 5633 2000 JRNL REFN ISSN 0021-9258 JRNL PMID 10681546 JRNL DOI 10.1074/JBC.275.8.5633 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,D.I.STUART,D.K.STAMMERS REMARK 1 TITL CRYSTALLOGRAPHIC ANALYSIS OF THE BINDING MODES OF REMARK 1 TITL 2 THIAZOLOISOINDOLINONE NON-NUCLEOSIDE INHIBITORS TO HIV-1 REMARK 1 TITL 3 REVERSE TRANSCRIPTASE AND COMPARISON WITH MODELING STUDIES. REMARK 1 REF J.MED.CHEM. V. 42 3845 1999 REMARK 1 REFN ISSN 0022-2623 REMARK 1 PMID 10508433 REMARK 1 DOI 10.1021/JM990275T REMARK 1 REFERENCE 2 REMARK 1 AUTH A.L.HOPKINS,J.REN,H.TANAKA,M.BABA,M.OKAMATO,D.I.STUART, REMARK 1 AUTH 2 D.K.STAMMERS REMARK 1 TITL DESIGN OF MKC-442 (EMIVIRINE) ANALOGUES WITH IMPROVED REMARK 1 TITL 2 ACTIVITY AGAINST DRUG-RESISTANT HIV MUTANTS. REMARK 1 REF J.MED.CHEM. V. 42 4500 1999 REMARK 1 REFN ISSN 0022-2623 REMARK 1 PMID 10579814 REMARK 1 DOI 10.1021/JM990192C REMARK 1 REFERENCE 3 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,J.WARREN,J.BALZARINI, REMARK 1 AUTH 2 D.I.STUART,D.K.STAMMERS REMARK 1 TITL CRYSTAL STRUCTURES OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX REMARK 1 TITL 2 WITH CARBOXANILIDE DERIVATIVES. REMARK 1 REF BIOCHEMISTRY V. 37 14394 1998 REMARK 1 REFN ISSN 0006-2960 REMARK 1 PMID 9772165 REMARK 1 DOI 10.1021/BI981309M REMARK 1 REFERENCE 4 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,E.Y.JONES,I.KIRBY,J.KEELING, REMARK 1 AUTH 2 C.K.ROSS,B.A.LARDER,D.I.STUART,D.K.STAMMERS REMARK 1 TITL 3'-AZIDO-3'-DEOXYTHYMIDINE DRUG RESISTANCE MUTATIONS IN REMARK 1 TITL 2 HIV-1 REVERSE TRANSCRIPTASE CAN INDUCE LONG RANGE REMARK 1 TITL 3 CONFORMATIONAL CHANGES. REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 95 9518 1998 REMARK 1 REFN ISSN 0027-8424 REMARK 1 PMID 9689112 REMARK 1 DOI 10.1073/PNAS.95.16.9518 REMARK 1 REFERENCE 5 REMARK 1 AUTH R.M.ESNOUF,J.REN,E.F.GARMAN,D.O.SOMERS,C.K.ROSS,E.Y.JONES, REMARK 1 AUTH 2 D.K.STAMMERS,D.I.STUART REMARK 1 TITL CONTINUOUS AND DISCONTINUOUS CHANGES IN THE UNIT CELL OF REMARK 1 TITL 2 HIV-1 REVERSE TRANSCRIPTASE CRYSTALS ON DEHYDRATION. REMARK 1 REF ACTA CRYSTALLOGR.,SECT.D V. 54 938 1998 REMARK 1 REFN ISSN 0907-4449 REMARK 1 PMID 9757109 REMARK 1 DOI 10.1107/S0907444998004284 REMARK 1 REFERENCE 6 REMARK 1 AUTH R.M.ESNOUF,J.REN,A.L.HOPKINS,C.K.ROSS,E.Y.JONES, REMARK 1 AUTH 2 D.K.STAMMERS,D.I.STUART REMARK 1 TITL UNIQUE FEATURES IN THE STRUCTURE OF THE COMPLEX BETWEEN REMARK 1 TITL 2 HIV-1 REVERSE TRANSCRIPTASE AND THE REMARK 1 TITL 3 BIS(HETEROARYL)PIPERAZINE (BHAP) U-90152 EXPLAIN RESISTANCE REMARK 1 TITL 4 MUTATIONS FOR THIS NONNUCLEOSIDE INHIBITOR. REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 94 3984 1997 REMARK 1 REFN ISSN 0027-8424 REMARK 1 PMID 9108091 REMARK 1 DOI 10.1073/PNAS.94.8.3984 REMARK 1 REFERENCE 7 REMARK 1 AUTH A.L.HOPKINS,J.REN,R.M.ESNOUF,B.E.WILLCOX,E.Y.JONES,C.ROSS, REMARK 1 AUTH 2 T.MIYASAKA,R.T.WALKER,H.TANAKA,D.K.STAMMERS,D.I.STUART REMARK 1 TITL COMPLEXES OF HIV-1 REVERSE TRANSCRIPTASE WITH INHIBITORS OF REMARK 1 TITL 2 THE HEPT SERIES REVEAL CONFORMATIONAL CHANGES RELEVANT TO REMARK 1 TITL 3 THE DESIGN OF POTENT NON-NUCLEOSIDE INHIBITORS. REMARK 1 REF J.MED.CHEM. V. 39 1589 1996 REMARK 1 REFN ISSN 0022-2623 REMARK 1 PMID 8648598 REMARK 1 DOI 10.1021/JM960056X REMARK 1 REFERENCE 8 REMARK 1 AUTH J.REN,R.ESNOUF,A.HOPKINS,C.ROSS,Y.JONES,D.STAMMERS,D.STUART REMARK 1 TITL THE STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH REMARK 1 TITL 2 9-CHLORO-TIBO: LESSONS FOR INHIBITOR DESIGN. REMARK 1 REF STRUCTURE V. 3 915 1995 REMARK 1 REFN ISSN 0969-2126 REMARK 1 PMID 8535785 REMARK 1 DOI 10.1021/JM990275T REMARK 1 REFERENCE 9 REMARK 1 AUTH J.REN,R.ESNOUF,E.GARMAN,D.SOMERS,C.ROSS,I.KIRBY,J.KEELING, REMARK 1 AUTH 2 G.DARBY,Y.JONES,D.STUART REMARK 1 TITL HIGH RESOLUTION STRUCTURES OF HIV-1 RT FROM FOUR REMARK 1 TITL 2 RT-INHIBITOR COMPLEXES. REMARK 1 REF NAT.STRUCT.BIOL. V. 2 293 1995 REMARK 1 REFN ISSN 1072-8368 REMARK 1 PMID 7540934 REMARK 1 DOI 10.1021/JM990192C REMARK 1 REFERENCE 10 REMARK 1 AUTH R.ESNOUF,J.REN,C.ROSS,Y.JONES,D.STAMMERS,D.STUART REMARK 1 TITL MECHANISM OF INHIBITION OF HIV-1 REVERSE TRANSCRIPTASE BY REMARK 1 TITL 2 NON-NUCLEOSIDE INHIBITORS. REMARK 1 REF NAT.STRUCT.BIOL. V. 2 303 1995 REMARK 1 REFN ISSN 1072-8368 REMARK 1 PMID 7540935 REMARK 1 DOI 10.1021/BI981309M REMARK 1 REFERENCE 11 REMARK 1 AUTH D.K.STAMMERS,D.O.SOMERS,C.K.ROSS,I.KIRBY,P.H.RAY,J.E.WILSON, REMARK 1 AUTH 2 M.NORMAN,J.S.REN,R.M.ESNOUF,E.F.GARMAN REMARK 1 TITL CRYSTALS OF HIV-1 REVERSE TRANSCRIPTASE DIFFRACTING TO 2.2 A REMARK 1 TITL 2 RESOLUTION. REMARK 1 REF J.MOL.BIOL. V. 242 586 1994 REMARK 1 REFN ISSN 0022-2836 REMARK 1 PMID 7523679 REMARK 1 DOI 10.1073/PNAS.95.16.9518 REMARK 2 REMARK 2 RESOLUTION. 2.80 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.80 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 95.0 REMARK 3 NUMBER OF REFLECTIONS : 24936 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.224 REMARK 3 FREE R VALUE : 0.295 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 1205 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 7637 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 24 REMARK 3 SOLVENT ATOMS : 26 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 1.400 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: REMARK 3 DUE TO THE LOW RATIO BETWEEN THE NUMBER OF REMARK 3 REFLECTIONS AND THE NUMBER OF PARAMETERS TO BE REMARK 3 REFINED, POSITIONAL RESTRAINTS WERE APPLIED TO ALL REMARK 3 ATOMS DISTANT FROM THE NNRTI-BINDING SITE (DEFINED AS REMARK 3 GREATER THAN 25 ANSTROM FROM THE CA ATOM OF RESIDUE REMARK 3 188) THROUGHOUT THE REFINEMENT. REMARK 4 REMARK 4 1DTQ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 26-JAN-00. REMARK 100 THE DEPOSITION ID IS D_1000010358. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 01-JAN-95 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SRS REMARK 200 BEAMLINE : PX7.2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.488 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 25847 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.800 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -1.500 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 95.9 REMARK 200 DATA REDUNDANCY : 3.450 REMARK 200 R MERGE (I) : 0.09800 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 8.3000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.80 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.90 REMARK 200 COMPLETENESS FOR SHELL (%) : 82.6 REMARK 200 DATA REDUNDANCY IN SHELL : 2.52 REMARK 200 R MERGE FOR SHELL (I) : 0.52500 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: X-PLOR REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 44.79 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.23 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: SEE REFERENCE 11, PH 5, VAPOR REMARK 280 DIFFUSION, SITTING DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 68.55000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 32.80000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 57.50000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 32.80000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 68.55000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 57.50000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5640 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 45080 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -32.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 PRO A 1 REMARK 465 ILE A 2 REMARK 465 SER A 3 REMARK 465 GLY A 444 REMARK 465 ALA A 445 REMARK 465 ALA A 446 REMARK 465 ASN A 447 REMARK 465 ARG A 448 REMARK 465 GLU A 449 REMARK 465 THR A 450 REMARK 465 LYS A 451 REMARK 465 LEU A 452 REMARK 465 GLY A 453 REMARK 465 LYS A 454 REMARK 465 LYS A 540 REMARK 465 GLY A 541 REMARK 465 ILE A 542 REMARK 465 GLY A 543 REMARK 465 GLY A 544 REMARK 465 ASN A 545 REMARK 465 GLU A 546 REMARK 465 GLN A 547 REMARK 465 VAL A 548 REMARK 465 ASP A 549 REMARK 465 LYS A 550 REMARK 465 LEU A 551 REMARK 465 VAL A 552 REMARK 465 SER A 553 REMARK 465 ALA A 554 REMARK 465 GLY A 555 REMARK 465 ILE A 556 REMARK 465 ARG A 557 REMARK 465 LYS A 558 REMARK 465 VAL A 559 REMARK 465 LEU A 560 REMARK 465 PRO B 1 REMARK 465 ILE B 2 REMARK 465 SER B 3 REMARK 465 PRO B 4 REMARK 465 LEU B 214 REMARK 465 THR B 215 REMARK 465 THR B 216 REMARK 465 PRO B 217 REMARK 465 ASP B 218 REMARK 465 LYS B 219 REMARK 465 LYS B 220 REMARK 465 HIS B 221 REMARK 465 GLN B 222 REMARK 465 LYS B 223 REMARK 465 GLU B 224 REMARK 465 PRO B 225 REMARK 465 PRO B 226 REMARK 465 PHE B 227 REMARK 465 LEU B 228 REMARK 465 TRP B 229 REMARK 465 MET B 230 REMARK 465 MET B 357 REMARK 465 ARG B 358 REMARK 465 GLY B 359 REMARK 465 ALA B 360 REMARK 465 HIS B 361 REMARK 465 LEU B 429 REMARK 465 GLU B 430 REMARK 465 LYS B 431 REMARK 465 GLU B 432 REMARK 465 PRO B 433 REMARK 465 ILE B 434 REMARK 465 VAL B 435 REMARK 465 GLY B 436 REMARK 465 ALA B 437 REMARK 465 GLU B 438 REMARK 465 THR B 439 REMARK 465 PHE B 440 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 PRO B 421 C - N - CA ANGL. DEV. = 10.5 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PRO A 52 10.47 -68.77 REMARK 500 TYR A 56 154.54 -40.17 REMARK 500 ASN A 57 129.40 174.36 REMARK 500 LYS A 70 -177.01 -172.52 REMARK 500 GLN A 85 159.22 -44.69 REMARK 500 GLU A 89 137.67 74.39 REMARK 500 VAL A 90 169.69 -42.92 REMARK 500 ILE A 135 -73.24 -47.81 REMARK 500 THR A 139 -157.38 -151.69 REMARK 500 PRO A 140 -90.45 -59.91 REMARK 500 VAL A 148 -160.02 -111.15 REMARK 500 PRO A 170 -73.52 -49.57 REMARK 500 MET A 184 -109.19 61.68 REMARK 500 ILE A 195 -68.46 -12.92 REMARK 500 HIS A 198 -74.76 -51.83 REMARK 500 ARG A 199 -18.56 -37.81 REMARK 500 LYS A 219 -55.03 -29.55 REMARK 500 GLN A 222 -147.81 -73.86 REMARK 500 PRO A 225 153.84 -49.26 REMARK 500 MET A 230 60.92 20.33 REMARK 500 PRO A 243 121.43 -24.82 REMARK 500 GLU A 248 31.13 -95.40 REMARK 500 LYS A 249 153.82 -42.65 REMARK 500 SER A 268 -31.16 -38.45 REMARK 500 ILE A 270 -39.39 -145.51 REMARK 500 PRO A 321 -11.30 -48.21 REMARK 500 PRO A 345 95.01 -25.84 REMARK 500 TYR A 354 109.77 -164.18 REMARK 500 TRP A 402 -89.24 -42.26 REMARK 500 PRO A 412 -177.85 -45.98 REMARK 500 ASN A 418 77.64 -66.60 REMARK 500 LYS A 465 77.03 -172.11 REMARK 500 LEU A 469 -158.11 -151.31 REMARK 500 ASP A 471 75.64 44.74 REMARK 500 GLN A 487 -75.21 -39.09 REMARK 500 LYS A 528 163.15 -43.76 REMARK 500 PRO A 537 164.83 -48.10 REMARK 500 ALA A 538 -116.78 -56.31 REMARK 500 SER B 68 139.95 -171.74 REMARK 500 PHE B 77 11.17 -68.96 REMARK 500 GLN B 85 163.57 -44.67 REMARK 500 TRP B 88 82.95 -61.90 REMARK 500 ILE B 94 -95.87 77.07 REMARK 500 PRO B 95 -69.92 -99.90 REMARK 500 LYS B 101 -4.02 -49.18 REMARK 500 LYS B 103 50.32 -63.68 REMARK 500 LYS B 104 -97.77 56.09 REMARK 500 ASP B 121 123.67 -39.75 REMARK 500 ASN B 136 25.11 41.18 REMARK 500 SER B 162 -79.20 -40.48 REMARK 500 REMARK 500 THIS ENTRY HAS 63 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE FPT A 999 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1RTV RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH NEVIRAPINE REMARK 900 RELATED ID: 1RTH RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH 1051U91 REMARK 900 RELATED ID: 1VRU RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH ALPHA-APA REMARK 900 RELATED ID: 1RTI RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH HEPT REMARK 900 RELATED ID: 1RTJ RELATED DB: PDB REMARK 900 HIV-1 RT REMARK 900 RELATED ID: 1REV RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH 9-CL-TIBO REMARK 900 RELATED ID: 1RT1 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH MKC-442 REMARK 900 RELATED ID: 1RT2 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH TNK-651 REMARK 900 RELATED ID: 1KLM RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH BHAP (U-90152) REMARK 900 RELATED ID: 1RT3 RELATED DB: PDB REMARK 900 AZT DRUG RESISTANT HIV-1 RT MUTANT (RTMC) COMPLEXED WITH 1051U91 REMARK 900 RELATED ID: 1RT4 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH UC-781 REMARK 900 RELATED ID: 1RT5 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH UC-10 REMARK 900 RELATED ID: 1RT6 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH UC-38 REMARK 900 RELATED ID: 1RT7 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH UC-84 REMARK 900 RELATED ID: 1C0T RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH BM+21.1326 REMARK 900 RELATED ID: 1C0U RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH BM+50.0934 REMARK 900 RELATED ID: 1C1B RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH GCA-186 REMARK 900 RELATED ID: 1C1C RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH TNK-6123 REMARK 900 RELATED ID: 1DTT RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH PETT-2 DBREF 1DTQ A 1 560 UNP P04585 POL_HV1H2 587 1146 DBREF 1DTQ B 1 440 UNP P04585 POL_HV1H2 587 1026 SEQRES 1 A 560 PRO ILE SER PRO ILE GLU THR VAL PRO VAL LYS LEU LYS SEQRES 2 A 560 PRO GLY MET ASP GLY PRO LYS VAL LYS GLN TRP PRO LEU SEQRES 3 A 560 THR GLU GLU LYS ILE LYS ALA LEU VAL GLU ILE CYS THR SEQRES 4 A 560 GLU MET GLU LYS GLU GLY LYS ILE SER LYS ILE GLY PRO SEQRES 5 A 560 GLU ASN PRO TYR ASN THR PRO VAL PHE ALA ILE LYS LYS SEQRES 6 A 560 LYS ASP SER THR LYS TRP ARG LYS LEU VAL ASP PHE ARG SEQRES 7 A 560 GLU LEU ASN LYS ARG THR GLN ASP PHE TRP GLU VAL GLN SEQRES 8 A 560 LEU GLY ILE PRO HIS PRO ALA GLY LEU LYS LYS LYS LYS SEQRES 9 A 560 SER VAL THR VAL LEU ASP VAL GLY ASP ALA TYR PHE SER SEQRES 10 A 560 VAL PRO LEU ASP GLU ASP PHE ARG LYS TYR THR ALA PHE SEQRES 11 A 560 THR ILE PRO SER ILE ASN ASN GLU THR PRO GLY ILE ARG SEQRES 12 A 560 TYR GLN TYR ASN VAL LEU PRO GLN GLY TRP LYS GLY SER SEQRES 13 A 560 PRO ALA ILE PHE GLN SER SER MET THR LYS ILE LEU GLU SEQRES 14 A 560 PRO PHE ARG LYS GLN ASN PRO ASP ILE VAL ILE TYR GLN SEQRES 15 A 560 TYR MET ASP ASP LEU TYR VAL GLY SER ASP LEU GLU ILE SEQRES 16 A 560 GLY GLN HIS ARG THR LYS ILE GLU GLU LEU ARG GLN HIS SEQRES 17 A 560 LEU LEU ARG TRP GLY LEU THR THR PRO ASP LYS LYS HIS SEQRES 18 A 560 GLN LYS GLU PRO PRO PHE LEU TRP MET GLY TYR GLU LEU SEQRES 19 A 560 HIS PRO ASP LYS TRP THR VAL GLN PRO ILE VAL LEU PRO SEQRES 20 A 560 GLU LYS ASP SER TRP THR VAL ASN ASP ILE GLN LYS LEU SEQRES 21 A 560 VAL GLY LYS LEU ASN TRP ALA SER GLN ILE TYR PRO GLY SEQRES 22 A 560 ILE LYS VAL ARG GLN LEU CSD LYS LEU LEU ARG GLY THR SEQRES 23 A 560 LYS ALA LEU THR GLU VAL ILE PRO LEU THR GLU GLU ALA SEQRES 24 A 560 GLU LEU GLU LEU ALA GLU ASN ARG GLU ILE LEU LYS GLU SEQRES 25 A 560 PRO VAL HIS GLY VAL TYR TYR ASP PRO SER LYS ASP LEU SEQRES 26 A 560 ILE ALA GLU ILE GLN LYS GLN GLY GLN GLY GLN TRP THR SEQRES 27 A 560 TYR GLN ILE TYR GLN GLU PRO PHE LYS ASN LEU LYS THR SEQRES 28 A 560 GLY LYS TYR ALA ARG MET ARG GLY ALA HIS THR ASN ASP SEQRES 29 A 560 VAL LYS GLN LEU THR GLU ALA VAL GLN LYS ILE THR THR SEQRES 30 A 560 GLU SER ILE VAL ILE TRP GLY LYS THR PRO LYS PHE LYS SEQRES 31 A 560 LEU PRO ILE GLN LYS GLU THR TRP GLU THR TRP TRP THR SEQRES 32 A 560 GLU TYR TRP GLN ALA THR TRP ILE PRO GLU TRP GLU PHE SEQRES 33 A 560 VAL ASN THR PRO PRO LEU VAL LYS LEU TRP TYR GLN LEU SEQRES 34 A 560 GLU LYS GLU PRO ILE VAL GLY ALA GLU THR PHE TYR VAL SEQRES 35 A 560 ASP GLY ALA ALA ASN ARG GLU THR LYS LEU GLY LYS ALA SEQRES 36 A 560 GLY TYR VAL THR ASN ARG GLY ARG GLN LYS VAL VAL THR SEQRES 37 A 560 LEU THR ASP THR THR ASN GLN LYS THR GLU LEU GLN ALA SEQRES 38 A 560 ILE TYR LEU ALA LEU GLN ASP SER GLY LEU GLU VAL ASN SEQRES 39 A 560 ILE VAL THR ASP SER GLN TYR ALA LEU GLY ILE ILE GLN SEQRES 40 A 560 ALA GLN PRO ASP GLN SER GLU SER GLU LEU VAL ASN GLN SEQRES 41 A 560 ILE ILE GLU GLN LEU ILE LYS LYS GLU LYS VAL TYR LEU SEQRES 42 A 560 ALA TRP VAL PRO ALA HIS LYS GLY ILE GLY GLY ASN GLU SEQRES 43 A 560 GLN VAL ASP LYS LEU VAL SER ALA GLY ILE ARG LYS VAL SEQRES 44 A 560 LEU SEQRES 1 B 440 PRO ILE SER PRO ILE GLU THR VAL PRO VAL LYS LEU LYS SEQRES 2 B 440 PRO GLY MET ASP GLY PRO LYS VAL LYS GLN TRP PRO LEU SEQRES 3 B 440 THR GLU GLU LYS ILE LYS ALA LEU VAL GLU ILE CYS THR SEQRES 4 B 440 GLU MET GLU LYS GLU GLY LYS ILE SER LYS ILE GLY PRO SEQRES 5 B 440 GLU ASN PRO TYR ASN THR PRO VAL PHE ALA ILE LYS LYS SEQRES 6 B 440 LYS ASP SER THR LYS TRP ARG LYS LEU VAL ASP PHE ARG SEQRES 7 B 440 GLU LEU ASN LYS ARG THR GLN ASP PHE TRP GLU VAL GLN SEQRES 8 B 440 LEU GLY ILE PRO HIS PRO ALA GLY LEU LYS LYS LYS LYS SEQRES 9 B 440 SER VAL THR VAL LEU ASP VAL GLY ASP ALA TYR PHE SER SEQRES 10 B 440 VAL PRO LEU ASP GLU ASP PHE ARG LYS TYR THR ALA PHE SEQRES 11 B 440 THR ILE PRO SER ILE ASN ASN GLU THR PRO GLY ILE ARG SEQRES 12 B 440 TYR GLN TYR ASN VAL LEU PRO GLN GLY TRP LYS GLY SER SEQRES 13 B 440 PRO ALA ILE PHE GLN SER SER MET THR LYS ILE LEU GLU SEQRES 14 B 440 PRO PHE ARG LYS GLN ASN PRO ASP ILE VAL ILE TYR GLN SEQRES 15 B 440 TYR MET ASP ASP LEU TYR VAL GLY SER ASP LEU GLU ILE SEQRES 16 B 440 GLY GLN HIS ARG THR LYS ILE GLU GLU LEU ARG GLN HIS SEQRES 17 B 440 LEU LEU ARG TRP GLY LEU THR THR PRO ASP LYS LYS HIS SEQRES 18 B 440 GLN LYS GLU PRO PRO PHE LEU TRP MET GLY TYR GLU LEU SEQRES 19 B 440 HIS PRO ASP LYS TRP THR VAL GLN PRO ILE VAL LEU PRO SEQRES 20 B 440 GLU LYS ASP SER TRP THR VAL ASN ASP ILE GLN LYS LEU SEQRES 21 B 440 VAL GLY LYS LEU ASN TRP ALA SER GLN ILE TYR PRO GLY SEQRES 22 B 440 ILE LYS VAL ARG GLN LEU CYS LYS LEU LEU ARG GLY THR SEQRES 23 B 440 LYS ALA LEU THR GLU VAL ILE PRO LEU THR GLU GLU ALA SEQRES 24 B 440 GLU LEU GLU LEU ALA GLU ASN ARG GLU ILE LEU LYS GLU SEQRES 25 B 440 PRO VAL HIS GLY VAL TYR TYR ASP PRO SER LYS ASP LEU SEQRES 26 B 440 ILE ALA GLU ILE GLN LYS GLN GLY GLN GLY GLN TRP THR SEQRES 27 B 440 TYR GLN ILE TYR GLN GLU PRO PHE LYS ASN LEU LYS THR SEQRES 28 B 440 GLY LYS TYR ALA ARG MET ARG GLY ALA HIS THR ASN ASP SEQRES 29 B 440 VAL LYS GLN LEU THR GLU ALA VAL GLN LYS ILE THR THR SEQRES 30 B 440 GLU SER ILE VAL ILE TRP GLY LYS THR PRO LYS PHE LYS SEQRES 31 B 440 LEU PRO ILE GLN LYS GLU THR TRP GLU THR TRP TRP THR SEQRES 32 B 440 GLU TYR TRP GLN ALA THR TRP ILE PRO GLU TRP GLU PHE SEQRES 33 B 440 VAL ASN THR PRO PRO LEU VAL LYS LEU TRP TYR GLN LEU SEQRES 34 B 440 GLU LYS GLU PRO ILE VAL GLY ALA GLU THR PHE MODRES 1DTQ CSD A 280 CYS 3-SULFINOALANINE HET CSD A 280 8 HET FPT A 999 24 HETNAM CSD 3-SULFINOALANINE HETNAM FPT N-[[3-FLUORO-4-ETHOXY-PYRID-2-YL]ETHYL]-N'-[5- HETNAM 2 FPT NITRILOMETHYL-PYRIDYL]-THIOUREA HETSYN CSD S-CYSTEINESULFINIC ACID; S-SULFINOCYSTEINE FORMUL 1 CSD C3 H7 N O4 S FORMUL 3 FPT C16 H16 F N5 O S FORMUL 4 HOH *26(H2 O) HELIX 1 1 THR A 27 GLU A 44 1 18 HELIX 2 2 PHE A 77 THR A 84 1 8 HELIX 3 3 HIS A 96 LEU A 100 5 5 HELIX 4 4 ASP A 121 LYS A 126 1 6 HELIX 5 5 TYR A 127 ALA A 129 5 3 HELIX 6 6 GLY A 155 ASN A 175 1 21 HELIX 7 7 GLU A 194 ARG A 211 1 18 HELIX 8 8 ASP A 218 GLN A 222 5 5 HELIX 9 9 THR A 253 GLN A 269 1 17 HELIX 10 10 THR A 296 GLU A 312 1 17 HELIX 11 11 ASN A 363 GLY A 384 1 22 HELIX 12 12 GLN A 394 TYR A 405 1 12 HELIX 13 13 THR A 473 SER A 489 1 17 HELIX 14 14 SER A 499 ALA A 508 1 10 HELIX 15 15 SER A 515 LYS A 528 1 14 HELIX 16 16 THR B 27 GLU B 44 1 18 HELIX 17 17 PHE B 77 ARG B 83 1 7 HELIX 18 18 GLY B 99 LYS B 103 5 5 HELIX 19 19 GLY B 112 VAL B 118 5 7 HELIX 20 20 ASP B 121 LYS B 126 1 6 HELIX 21 21 TYR B 127 ALA B 129 5 3 HELIX 22 22 SER B 134 GLU B 138 5 5 HELIX 23 23 LYS B 154 ASN B 175 1 22 HELIX 24 24 GLU B 194 ARG B 211 1 18 HELIX 25 25 HIS B 235 TRP B 239 5 5 HELIX 26 26 THR B 253 SER B 268 1 16 HELIX 27 27 VAL B 276 LYS B 281 1 6 HELIX 28 28 THR B 296 LEU B 310 1 15 HELIX 29 29 ASN B 363 GLY B 384 1 22 HELIX 30 30 GLN B 394 TRP B 406 1 13 HELIX 31 31 PRO B 420 TYR B 427 1 8 SHEET 1 A 3 ILE A 47 LYS A 49 0 SHEET 2 A 3 ILE A 142 TYR A 146 -1 O GLN A 145 N SER A 48 SHEET 3 A 3 PHE A 130 ILE A 132 -1 N PHE A 130 O TYR A 144 SHEET 1 B 2 VAL A 60 ILE A 63 0 SHEET 2 B 2 ARG A 72 VAL A 75 -1 N ARG A 72 O ILE A 63 SHEET 1 C 3 SER A 105 ASP A 110 0 SHEET 2 C 3 ASP A 186 SER A 191 -1 O LEU A 187 N LEU A 109 SHEET 3 C 3 VAL A 179 GLN A 182 -1 O VAL A 179 N GLY A 190 SHEET 1 D 4 PHE A 227 TRP A 229 0 SHEET 2 D 4 TYR A 232 LEU A 234 -1 N TYR A 232 O TRP A 229 SHEET 3 D 4 LYS A 238 VAL A 241 -1 O THR A 240 N GLU A 233 SHEET 4 D 4 GLY A 316 VAL A 317 -1 N GLY A 316 O TRP A 239 SHEET 1 E 5 LYS A 347 TYR A 354 0 SHEET 2 E 5 GLN A 336 GLU A 344 -1 N TRP A 337 O TYR A 354 SHEET 3 E 5 ILE A 326 GLY A 333 -1 N ILE A 326 O TYR A 342 SHEET 4 E 5 LYS A 388 LEU A 391 1 O LYS A 388 N ALA A 327 SHEET 5 E 5 TRP A 414 PHE A 416 1 N GLU A 415 O PHE A 389 SHEET 1 F 2 HIS A 361 THR A 362 0 SHEET 2 F 2 GLN A 512 SER A 513 -1 N GLN A 512 O THR A 362 SHEET 1 G 3 GLU A 438 TYR A 441 0 SHEET 2 G 3 GLU A 492 THR A 497 1 O GLU A 492 N GLU A 438 SHEET 3 G 3 LYS A 530 TRP A 535 1 O LYS A 530 N VAL A 493 SHEET 1 H 3 ILE B 47 LYS B 49 0 SHEET 2 H 3 ILE B 142 TYR B 146 -1 O GLN B 145 N SER B 48 SHEET 3 H 3 PHE B 130 ILE B 132 -1 N PHE B 130 O TYR B 144 SHEET 1 I 2 VAL B 60 LYS B 64 0 SHEET 2 I 2 TRP B 71 VAL B 75 -1 N ARG B 72 O ILE B 63 SHEET 1 J 3 SER B 105 ASP B 110 0 SHEET 2 J 3 ASP B 186 SER B 191 -1 O LEU B 187 N LEU B 109 SHEET 3 J 3 VAL B 179 TYR B 183 -1 O VAL B 179 N GLY B 190 SHEET 1 K 5 LYS B 347 ALA B 355 0 SHEET 2 K 5 GLN B 336 GLU B 344 -1 N TRP B 337 O TYR B 354 SHEET 3 K 5 ILE B 326 GLY B 333 -1 N ILE B 326 O TYR B 342 SHEET 4 K 5 LYS B 388 LEU B 391 1 O LYS B 388 N ALA B 327 SHEET 5 K 5 GLU B 413 PHE B 416 1 O GLU B 413 N PHE B 389 LINK C LEU A 279 N CSD A 280 1555 1555 1.33 CISPEP 1 PRO A 225 PRO A 226 0 -0.47 CISPEP 2 PRO A 420 PRO A 421 0 -0.45 CISPEP 3 ILE B 94 PRO B 95 0 -0.42 SITE 1 AC1 10 LYS A 101 LYS A 103 VAL A 179 TYR A 181 SITE 2 AC1 10 TYR A 188 LEU A 234 HIS A 235 PRO A 236 SITE 3 AC1 10 TYR A 318 GLU B 138 CRYST1 137.100 115.000 65.600 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.007294 0.000000 0.000000 0.00000 SCALE2 0.000000 0.008696 0.000000 0.00000 SCALE3 0.000000 0.000000 0.015244 0.00000